Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, Aug. 12, 2025 at 10:30 A.M. EDT. The ...

The company formerly known a Sosei Heptares unveiled new weight loss programs. Elsewhere, BridgeBio and Madrigal unveiled ...

Madrigal Pharmaceuticals (MDGL) stock gains as the company's Q2 2025 results exceed expectations with a 15-fold surge in ...

Second-quarter 2025 Rezdiffra™ (resmetirom) net sales of $212.8 millionAs of June 30, 2025, more than 23,000 patients on Rezdiffra Received new U.S. Rezdiffra patent providing protection to Feb. 4, ...

West Conshohocken’s Madrigal Pharmaceuticals earned a major win with the FDA approval of its first commercial product, reports John George for the Philadelphia ...

Among last week’s news, US biotech Celcuity leapt 180% on new Phase III data for its cancer drug candidate gedatolisib. US drugmaker Madrigal Pharmaceuticals entered into a licensing deal with China’s ...

GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is ...

Strong Q1 sales of $137.3M showcase Madrigal Pharmaceuticals, Inc.'s Rezdiffra's growth in non-cirrhotic NASH. Click for my ...

License agreement supports Madrigal's pipeline strategy to develop innovative combination treatments for MASH, anchored by its foundational therapy Rezdiffra (resmetirom) Combining Rezdiffra with the ...

DelveInsight's THR-β Agonist Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

Madrigal Pharmaceuticals secures global rights to SYH2086, aiming to enhance MASH treatment with innovative combination ...